<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation of adults with cutaneous lesions of vasculitis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation of adults with cutaneous lesions of vasculitis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation of adults with cutaneous lesions of vasculitis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicole Fett, MD, MSCE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 01, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H16171969">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous vasculitis comprises a diverse group of conditions characterized by acute, relapsing, or chronic inflammatory damage to small or medium-sized blood vessels in the skin or subcutaneous tissue. Cutaneous vasculitis can occur as a feature of multiple disorders and exhibits a wide variety of clinical manifestations. Examples of clinical findings include petechiae, palpable purpura, hemorrhagic bullae, nodules, ulcers, livedo reticularis, livedo racemosa, and urticaria.
        </p>
        <p>
         Although cutaneous vasculitis can be a benign, transient condition, it may also be an indicator of underlying disease or systemic vasculitis. Careful assessment is essential for accurate diagnosis and optimal management. A typical initial evaluation includes a skin biopsy to confirm vasculitis, careful review of the patient history to assess for the etiology of vasculitis, and laboratory tests to assess for systemic involvement. When the cause of vasculitis is uncertain, additional tests may be helpful.
        </p>
        <p>
         The general approach to the evaluation of adults with cutaneous lesions suggestive of vasculitis will be reviewed here. Overview discussions of vasculitis in adults and children and in-depth discussions of specific forms of vasculitis are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">
          "Vasculitis in children: Evaluation overview"
         </a>
         and
         <a class="local">
          'Types of cutaneous vasculitis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1605615338">
         <span class="h1">
          TYPES OF CUTANEOUS VASCULITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides provides a framework for the classification of vasculitides affecting the skin [
         <a href="#rid1">
          1
         </a>
         ]. Major groupings are based upon the size of vessels involved, propensity to affect other organs, and associated causes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small vessel vasculitis (primarily affects dermal vessels [arterioles, capillaries, venules]):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immune complex vasculitis:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura) (see
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis) (see
         <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">
          "Urticarial vasculitis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cryoglobulinemic vasculitis (see
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Microscopic polyangiitis (see
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (see
         <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">
          "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Granulomatosis with polyangiitis (see
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medium vessel vasculitis (primarily affects arteries in subcutaneous tissue):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cutaneous polyarteritis nodosa (see
         <a class="medical medical_review" href="/z/d/html/109628.html" rel="external">
          "Cutaneous polyarteritis nodosa"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Polyarteritis nodosa (see
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variable-vessel vasculitis (may affect any type of vessel):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Behçet disease (see
         <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">
          "Clinical manifestations and diagnosis of Behçet syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cogan syndrome (see
         <a class="medical medical_review" href="/z/d/html/8227.html" rel="external">
          "Cogan syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous single-organ vasculitis (skin-limited vasculitis that exhibits no association with systemic vasculitis):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cutaneous immunoglobulin M (IgM)/immunoglobulin G (IgG) immune complex vasculitis (leukocytoclastic vasculitis with IgG/IgM deposits that does not fit into another defined immune complex vasculitis)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nodular cutaneous vasculitis (erythema induratum of Bazin) (see
         <a class="medical medical_review" href="/z/d/html/109264.html" rel="external">
          "Erythema induratum (nodular vasculitis)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Erythema elevatum diutinum (see
         <a class="medical medical_review" href="/z/d/html/13765.html" rel="external">
          "Erythema elevatum diutinum"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Additional defined variants include vasculitis associated with systemic disease (eg, rheumatoid vasculitis, lupus vasculitis, etc) and vasculitis associated with a probable etiology (ie, associated with a specific drug, infection, sepsis, neoplasm, etc).
        </p>
        <p>
         Large vessel vasculitides, such as Takayasu arteritis and giant cell arteritis, typically do not affect vessels in the skin. Occasionally, giant cell arteritis results in cutaneous necrosis related to vascular compromise of vessels proximal to the skin [
         <a href="#rid1">
          1
         </a>
         ]. Rarely, giant cell arteritis involves vessels in the panniculus [
         <a href="#rid1">
          1
         </a>
         ]. Kawasaki disease, a form of medium vessel vasculitis, also does not typically involve vessels in the skin. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults", section on 'Major categories of vasculitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1042866620">
         <span class="h1">
          WHEN TO SUSPECT CUTANEOUS VASCULITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Suspicion for cutaneous vasculitis typically arises based upon the detection of suggestive cutaneous findings.
        </p>
        <p class="headingAnchor" id="H665985760">
         <span class="h2">
          Suggestive findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous vasculitis may exhibit a variety of morphologies, which usually correlate with the pathologic processes occurring in the skin [
         <a href="#rid2">
          2-4
         </a>
         ]. Clinical features can include manifestations typical of small vessel involvement (eg, petechiae, palpable purpura, hemorrhagic bullae, superficial ulceration, urticaria) or medium vessel involvement (eg, subcutaneous nodules, deep ulcers, livedo reticularis, livedo racemosa). The skin lesions are often asymptomatic but may be associated with pruritus, burning sensations, or pain.
        </p>
        <p>
         Examination of the entire skin surface can be helpful for the assessment for cutaneous vasculitis. Cutaneous vasculitis most commonly occurs in a symmetrical distribution on the lower legs, dependent areas, or on areas of constrictive clothing due to increased hydrostatic pressure in these locations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Petechiae
         </strong>
         – Petechiae are nonblanchable and nonpalpable, pinpoint macules (less than a few millimeters in diameter) that result from capillary inflammation and red blood cell extravasation  (
         <a class="graphic graphic_picture graphicRef58626" href="/z/d/graphic/58626.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Petechiae are nonblanchable due to the presence of extravasated erythrocytes in the dermis due to damaged vessel walls. Diascopy (the application of pressure to a skin lesion with a glass slide) is a helpful technique for identifying nonblanchable lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Palpable purpura
         </strong>
         – Brisk inflammation of venules and arterioles initially manifests as infiltrated, erythematous papules and plaques. These progress to raised, nonblanchable (purpuric) lesions as damage to vessel walls increases  (
         <a class="graphic graphic_picture graphicRef79783 graphicRef122867 graphicRef70300" href="/z/d/graphic/79783.html" rel="external">
          picture 2A-C
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. As with petechiae, diascopy can be used to confirm nonblanchable lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemorrhagic bullae
         </strong>
         – Small vessel involvement in the dermis can result in necrosis of overlying skin with associated blisters and extravasation of red blood cells  (
         <a class="graphic graphic_picture graphicRef57440" href="/z/d/graphic/57440.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subcutaneous nodules
         </strong>
         – Intense inflammation of medium-sized vessels (vessels with muscular walls in the deep dermis and subcutis) can lead to the formation of nodular lesions  (
         <a class="graphic graphic_picture graphicRef75828" href="/z/d/graphic/75828.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ulceration or digital necrosis
         </strong>
         – Ulceration and tissue necrosis occur when vasculitis results in reduced vascular perfusion in the skin  (
         <a class="graphic graphic_picture graphicRef75391 graphicRef58586" href="/z/d/graphic/75391.html" rel="external">
          picture 5A-B
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Superficial ulcers can occur in patients with small vessel vasculitis; deep ulcers are usually the result of medium vessel disease [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Livedo reticularis and livedo racemosa
         </strong>
         – Livedo reticularis presents as a localized or widespread, patchy, reticulated, vascular network with a red-blue or violaceous hue  (
         <a class="graphic graphic_picture graphicRef79545 graphicRef61842" href="/z/d/graphic/79545.html" rel="external">
          picture 6A-B
         </a>
         ). It results from compromise of blood flow in medium-sized vessels and can occur in the setting of vasculopathy due to vasospasm, hypercoagulable states, thrombosis, increased blood viscosity, or embolic phenomena, as well as in association with vasculitis. Livedo racemosa presents with a more abrupt and broken vascular pattern than livedo reticularis  (
         <a class="graphic graphic_picture graphicRef64023" href="/z/d/graphic/64023.html" rel="external">
          picture 7
         </a>
         ). It is strongly associated with Sneddon syndrome, a nonvasculitic disorder characterized by livedoid skin lesions and cerebrovascular accidents, but may also occur as a manifestation of medium vessel vasculitis and other disorders [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urticaria
         </strong>
         – Unlike nonvasculitic urticaria, lesions of urticarial vasculitis usually persist for more than 24 hours and are frequently associated with a burning sensation or pain, rather than pruritus. Lesions may contain purpuric areas and can resolve with hyperpigmentation  (
         <a class="graphic graphic_picture graphicRef60497" href="/z/d/graphic/60497.html" rel="external">
          picture 8
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">
          "Urticarial vasculitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1833261789">
         <span class="h2">
          Mimickers
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of a petechial or purpuric eruption does not always indicate vasculitis. Examples of other disorders that may present with these findings include [
         <a href="#rid7">
          7,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Common vasculitis mimickers:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pigmented purpuric dermatoses (eg, nonblanchable pinpoint macules, patches, or plaques, often on the lower legs)  (
         <a class="graphic graphic_picture graphicRef67127" href="/z/d/graphic/67127.html" rel="external">
          picture 9
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13757.html" rel="external">
          "Pigmented purpuric dermatoses (capillaritis)", section on 'Schamberg disease (progressive pigmentary purpura)'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Macular purpura due to chronic sun exposure, glucocorticoid therapy, trauma, or anticoagulants  (
         <a class="graphic graphic_picture graphicRef70793" href="/z/d/graphic/70793.html" rel="external">
          picture 10
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inflammatory disorders on the lower extremities or other dependent sites (eg, hemorrhagic macules or papules due to stasis dermatitis or maculopapular drug eruptions)  (
         <a class="graphic graphic_picture graphicRef72689 graphicRef80847" href="/z/d/graphic/72689.html" rel="external">
          picture 11A-B
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arthropod bites (eg, bedbugs)  (
         <a class="graphic graphic_picture graphicRef62345" href="/z/d/graphic/62345.html" rel="external">
          picture 12
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less common vasculitis mimickers:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pernio  (
         <a class="graphic graphic_picture graphicRef128356" href="/z/d/graphic/128356.html" rel="external">
          picture 13
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">
          "Pernio (chilblains)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Scurvy (perifollicular hemorrhage)  (
         <a class="graphic graphic_picture graphicRef51219" href="/z/d/graphic/51219.html" rel="external">
          picture 14
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">
          "Overview of water-soluble vitamins", section on 'Deficiency'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Platelet deficiencies or dysfunction (petechiae or macular purpura)  (
         <a class="graphic graphic_picture graphicRef76671" href="/z/d/graphic/76671.html" rel="external">
          picture 15
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercoagulable and thrombotic disorders (noninflammatory retiform purpura)  (
         <a class="graphic graphic_picture graphicRef65890 graphicRef65011" href="/z/d/graphic/65890.html" rel="external">
          picture 16A-B
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/16556.html" rel="external">
          "Approach to the patient with retiform (angulated) purpura"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cholesterol emboli (noninflammatory retiform purpura, digital gangrene, livedo reticularis)  (
         <a class="graphic graphic_picture graphicRef69150" href="/z/d/graphic/69150.html" rel="external">
          picture 17
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">
          "Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Septic emboli (petechiae on the distal extremities, noninflammatory retiform purpura)  (
         <a class="graphic graphic_picture graphicRef57118" href="/z/d/graphic/57118.html" rel="external">
          picture 18
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">
          "Complications and outcome of infective endocarditis", section on 'Metastatic infection'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic amyloidosis (periorbital and pinch purpura)  (
         <a class="graphic graphic_picture graphicRef77887" href="/z/d/graphic/77887.html" rel="external">
          picture 19
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13759.html" rel="external">
          "Cutaneous manifestations of amyloidosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Strongyloidiasis (periumbilical purpura) (see
         <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">
          "Strongyloidiasis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Purpura fulminans (sharply demarcated retiform purpura in the setting of disseminated intravascular coagulation or sepsis)  (
         <a class="graphic graphic_picture graphicRef53920" href="/z/d/graphic/53920.html" rel="external">
          picture 20
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">
          "Clinical manifestations of meningococcal infection", section on 'Purpura fulminans'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Calciphylaxis (painful retiform purpura in adipose-rich areas, livedo reticularis) (see
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         In addition, livedoid vasculopathy (also known as atrophie blanche) may be confused with vasculitis. Livedoid vasculopathy presents with punched-out ulcers on the lower legs with surrounding livedo reticularis or livedo racemosa  (
         <a class="graphic graphic_picture graphicRef52262" href="/z/d/graphic/52262.html" rel="external">
          picture 21
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4684.html" rel="external">
          "Livedoid vasculopathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16171984">
         <span class="h1">
          PATIENT ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of patients with cutaneous lesions of vasculitis focuses on confirming the presence of vasculitis, evaluating for extracutaneous involvement, and identifying the underlying cause. This typically involves consideration of a skin biopsy (or biopsies), careful review of the patient history and review of systems, and performance of select laboratory tests. A summary of the approach to patients with cutaneous features of small vessel vasculitis is provided in an algorithm  (
         <a class="graphic graphic_algorithm graphicRef138771" href="/z/d/graphic/138771.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1489819715">
         <span class="h2">
          Skin biopsy to confirm vasculitis
         </span>
        </p>
        <p class="headingAnchor" id="H532149708">
         <span class="h3">
          Indications for biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of cutaneous vasculitis may be strongly suspected based upon the physical examination; however, a biopsy is necessary for a definitive diagnosis.
        </p>
        <p>
         In general, a skin biopsy for routine histopathologic examination should be performed whenever feasible. However, clinicians with expertise in the evaluation of cutaneous vasculitis may elect to delay a biopsy for patients with classic presentations of acute small vessel cutaneous vasculitis that have persisted for less than four weeks, have a clear removable or treatable inciting factor (eg, drug or infection), and exhibit no clinical or laboratory evidence of systemic involvement because many such cases resolve spontaneously within a few weeks. If the vasculitis fails to improve within four weeks (ie, new lesions developing or persistence of red or purple lesions), performance of a skin biopsy is indicated. Of note, residual, macular or patchy hyperpigmentation is common after resolution of vasculitis lesions.
        </p>
        <p>
         When patients present with cutaneous features of small vessel vasculitis, an additional skin biopsy of lesional skin for direct immunofluorescence (DIF) may be performed at the same time as the biopsy for routine histopathologic examination to assess for IgA vasculitis. (See
         <a class="local">
          'Direct immunofluorescence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H606549">
         <span class="h3">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         A histologic diagnosis of cutaneous vasculitis is confirmed by the identification of findings that indicate an inflammatory process that results in damage to vessel walls [
         <a href="#rid2">
          2,4
         </a>
         ]. Small vessels (venules and arterioles) require two out of three of the following criteria for a definitive diagnosis of vasculitis [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiocentric and/or angioinvasive inflammatory infiltrates
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disruption and/or destruction of vessel walls by the inflammatory infiltrate
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibrinoid necrosis (fibrin deposition within the vessel wall or lumen; results from the accumulation and conversion of plasma proteins [
         <a href="#rid2">
          2
         </a>
         ])
        </p>
        <p>
        </p>
        <p>
         Medium-sized vessels (small arteries and veins) in the deep dermis and subcutaneous tissue require both of the following criteria to confirm vasculitis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory infiltrate infiltrating the muscular vessel wall
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibrinoid necrosis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3183073701">
         <span class="h3">
          Additional supportive findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other histopathologic findings that support but are not diagnostic for vasculitis include the presence of extravasated erythrocytes, nuclear debris (leukocytoclasia), necrosis of eccrine glands, endothelial cell damage swelling or necrosis, and cutaneous ulceration, infarction, or necrosis [
         <a href="#rid9">
          9
         </a>
         ]. Findings that suggest particular forms of vasculitis (eg, granulomas in granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis [Churg-Strauss syndrome] and interface dermatitis in vasculitis associated with lupus erythematosus or dermatomyositis) represent additional helpful information that can be gleaned from a biopsy. "Leukocytoclastic vasculitis" is a pathologic term that describes the microscopic findings of a neutrophilic small vessel vasculitis, a characteristic feature of multiple forms of cutaneous small vessel vasculitis.
        </p>
        <p class="headingAnchor" id="H4117924584">
         <span class="h3">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimizing the timing of the biopsy, biopsy depth, and biopsy location increases the likelihood of identifying diagnostic features.
        </p>
        <p class="headingAnchor" id="H1117827">
         <span class="h4">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic characteristics of vasculitic lesions evolve quickly. Selection of a lesion that the patient estimates has been present for
         <strong>
          24 to 48 hours
         </strong>
         for biopsy may optimize both the detection of vasculitis and assessment of the type of inflammatory infiltrate, a feature that can be helpful for diagnosis. Lesions that are between 24 and 48 hours old are the most likely to demonstrate diagnostic findings. Biopsies of leukocytoclastic vasculitis taken prior to 24 hours are likely to have some infiltration of neutrophils but often do not yet exhibit fibrinoid necrosis. Beyond 48 hours, the inflammatory infiltrate in leukocytoclastic vasculitis begins to shift from a neutrophilic infiltrate to lymphocytes and macrophages, and then eventually clears, leaving only evidence of fibrinoid necrosis. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above and
         <a class="local">
          'Additional supportive findings'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1117834">
         <span class="h4">
          Type of biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cutaneous features dictate the type of biopsy that should be performed. In general, shave biopsies should be avoided, as they prevent the evaluation of vessels in the mid-dermis and deep dermis. (See
         <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">
          "Skin biopsy techniques", section on 'Biopsy techniques'
         </a>
         .)
        </p>
        <p>
         The following principles are helpful for guiding the selection of the appropriate procedure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous findings suggestive of involvement of the vessels in the superficial to mid-dermis (petechiae, palpable purpura, or urticarial papules or plaques) should be evaluated with a punch biopsy that is 4 mm in diameter or larger. This allows for evaluation of vessels throughout the dermis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous findings suggestive of involvement of the vessels in the mid-dermis to the subcutaneous tissue (livedo racemosa, subcutaneous nodules, ulcers) require a large punch biopsy (8 to 10 mm) or wedge biopsy that includes the subcutaneous tissue.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H45090357">
         <span class="h4">
          Location
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cutaneous features determine the optimal location of the biopsy within the involved area. Biopsies of petechial lesions or palpable purpura can be taken from any site within the lesion.
        </p>
        <p>
         The ideal location of the biopsy differs in patients with livedo racemosa or ulcerations. In livedo racemosa, biopsy should be performed within the pale center of an erythematous ring [
         <a href="#rid2">
          2
         </a>
         ]. This is where the responsible vessel is likely to be located. When ulceration is present, the biopsy should be taken from the edge of the ulcer, rather than the ulcer itself. A biopsy taken from the base of an ulcer can reveal purely incidental findings of vascular injury that resemble the histopathologic findings of vasculitis [
         <a href="#rid9">
          9
         </a>
         ]. Biopsies of nodular lesions should be centered over a tender nodule.
        </p>
        <p>
         Biopsies of infarcted digits are generally low yield for evaluation for vasculitis, as the infarcted area is simply a manifestation of underlying vessel obstruction.
        </p>
        <p>
         Biopsies of livedo reticularis, a feature that may accompany vasculitis, demonstrate nonspecific histopathologic findings and are usually not indicated.
        </p>
        <p class="headingAnchor" id="H252714508">
         <span class="h4">
          Direct immunofluorescence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although an additional skin biopsy for direct immunofluorescence (DIF) is commonly performed at the same time as the biopsy for routine histopathologic examination in patients with findings suggestive of small vessel vasculitis, an immediate biopsy for DIF is not mandatory when small vessel vasculitis is acute (duration &lt;4 weeks) in the absence of symptoms or signs suggestive of systemic involvement because many of these cases resolve spontaneously. Reserving a biopsy for DIF for patients with small vessel vasculitis of unclear cause that persists for ≥4 weeks is a reasonable alternative. (See
         <a class="local">
          'Biopsy for direct immunofluorescence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4120694530">
         <span class="h2">
          Evaluation for etiology and extracutaneous involvement
         </span>
        </p>
        <p class="headingAnchor" id="H568775493">
         <span class="h3">
          Initial assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial assessment focuses on identifying readily identifiable causes of vasculitis and systemic involvement. Appropriate initial steps include an assessment for risk factors for vasculitis and performance of a review of systems and select laboratory tests.
        </p>
        <p class="headingAnchor" id="H1883590358">
         <span class="h4">
          Review of risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the cause of vasculitis can be elusive, the patient history is an important method for identifying the etiology of vasculitis. In particular, the history should assess for recent infections (particularly upper respiratory infections), drug exposure (including cocaine), connective tissue disease, and malignancy [
         <a href="#rid2">
          2,9,10
         </a>
         ]. In a study that pooled data from over 2000 patients in studies that reported triggering factors or associated conditions in patients with vasculitis, the frequencies of idiopathic disease, infections, drugs, connective tissue disease, IgA vasculitis, malignancy, and primary systemic vasculitides were 39, 23, 20, 12, 10, 4, and 4 percent, respectively [
         <a href="#rid9">
          9
         </a>
         ]. Other systemic disorders were less frequently reported. Rates of failure to identify the cause of vasculitis ranged from 3 to 72 percent of patients [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         In particular, when evaluating for drug-induced vasculitis, the timing of the development of vasculitis can be helpful. Drug-induced vasculitis most often occurs 7 to 10 days after the introduction of the inciting medication, with the exception of drug-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, which usually occurs a year or more after starting the causative medication [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2932989650">
         <span class="h4">
          Review of systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single-organ vasculitis limited to the skin is a diagnosis of exclusion. Patients should be questioned regarding signs or symptoms that could suggest systemic vasculitis or underlying disease  (
         <a class="graphic graphic_table graphicRef59048" href="/z/d/graphic/59048.html" rel="external">
          table 1
         </a>
         ). Examples of potentially helpful findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue, chills, night sweats
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myalgias or arthralgias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tea-colored urine or gross hematuria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal pain or melena
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyspnea, cough, or hemoptysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New-onset or worsening asthma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral neuropathy
        </p>
        <p>
        </p>
        <p>
         If these or other symptoms suggestive of systemic vasculitis or underlying disease are present, further testing guided by the specific symptoms present are indicated. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults", section on 'Clinical features suggestive of systemic vasculitis'
         </a>
         and
         <a class="local">
          'Additional studies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2705581256">
         <span class="h4">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine initial laboratory tests suggested for all patients with cutaneous vasculitis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood count with differential and platelets
         </strong>
         – Cytopenias may suggest underlying connective tissue disease, leukocytosis can suggest infection or hematologic malignancy, and platelet abnormalities may reflect nonvasculitic causes of skin lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comprehensive metabolic panel
         </strong>
         – Evaluates for renal and hepatic abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinalysis with microscopy
         </strong>
         – Identifies hematuria due to renal involvement.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3950793987">
         <span class="h3">
          Additional studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional evaluation is indicated for patients in whom the cause of persistent vasculitis (duration ≥4 weeks) is unclear or who present with symptoms, signs, or laboratory results suggestive of extracutaneous involvement or underlying disease. This may include screening laboratory tests, other tests directed by patient symptoms or test results, and a skin biopsy for DIF (if biopsy for DIF was not already performed).
        </p>
        <p class="headingAnchor" id="H541640332">
         <span class="h4">
          Laboratory and other tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical laboratory tests obtained to evaluate patients with either persistent vasculitis of unknown cause or systemic symptoms include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatitis B and C serologies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum complement levels (total hemolytic complement [CH50], C3, and C4)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antinuclear antibody (ANA) and anti-dsDNA, anti-Ro, anti-La, anti-RNP, and anti-Smith antibodies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatoid factor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum cryoglobulins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ANCA
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HIV antibody
        </p>
        <p>
        </p>
        <p>
         Positive ANCAs are helpful in the correct clinical context but do not confirm or eliminate a diagnosis of an ANCA-associated vasculitis. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Disease associations'
         </a>
         .)
        </p>
        <p>
         Additional laboratory tests or imaging studies are selected based upon the results of these tests and the presence of worrisome signs or symptoms  (
         <a class="graphic graphic_table graphicRef59048" href="/z/d/graphic/59048.html" rel="external">
          table 1
         </a>
         ). For example, review of systems that detects weight loss, joint pain, sicca symptoms, oral or nasal ulcerations, hair loss, photosensitivity, or Raynaud phenomenon supports a thorough evaluation for underlying connective tissue disorders.
        </p>
        <p>
         Pulmonary symptoms support performance of a chest radiograph and further evaluation as needed. ANCA-associated vasculitis can affect the small and medium vessels of the lung, causing inflammation and hemorrhage. Additionally, hypocomplementemic urticarial vasculitis syndrome, a subset of urticarial vasculitis, may present with hemoptysis, pleural effusion, and severe chronic obstructive pulmonary disease [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         Unexplained weight loss, fevers, chills, and night sweats may signify a malignancy and should prompt further evaluation. However, an extensive search for malignancy is not warranted in patients without signs or symptoms suggestive of malignancy given the rarity of this association (less than 5 percent of all patients with cutaneous vasculitis [
         <a href="#rid13">
          13-15
         </a>
         ]). Patients should be up-to-date on age-appropriate malignancy screening. Also, in addition to the standard complete blood count with differential, our evaluation of patients over the age of 60 who lack another identifiable cause of small vessel vasculitis includes serum protein electrophoresis and immunofixation and serum free light chains. Limiting imaging studies to those indicated based upon the presence of suggestive signs and symptoms is appropriate in this situation.
        </p>
        <p class="headingAnchor" id="H16171998">
         <span class="h4">
          Biopsy for direct immunofluorescence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Direct immunofluorescence (DIF) is an essential component of the evaluation of cutaneous vasculitis in adults with small vessel vasculitis of unclear cause that persists for ≥4 weeks. DIF utilizes labeled antibodies to identify immunoglobulin and complement deposits within the skin.
        </p>
        <p class="headingAnchor" id="H1117855">
         <span class="h5">
          Value
         </span>
         <span class="headingEndMark">
          —
         </span>
         DIF can aid in the identification of the underlying etiology of the vasculitis. DIF is particularly important for the diagnosis of IgA vasculitis (Henoch-Schönlein purpura). Renal involvement is common in IgA vasculitis, warranting additional monitoring. Only the identification of perivascular IgA deposition with DIF confirms the diagnosis of IgA vasculitis [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6407.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
         DIF is also of value for distinguishing immune complex-mediated vasculitides (such as most cases of cutaneous leukocytoclastic vasculitis, IgA vasculitis [Henoch-Schönlein purpura], cryoglobulinemic vasculitis, urticarial vasculitis, and vasculitis secondary to autoimmune connective tissue disease) from pauci-immune vasculitis (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis, and polyarteritis nodosa)  (
         <a class="graphic graphic_table graphicRef59048" href="/z/d/graphic/59048.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. A negative DIF in the setting of histopathologically confirmed vasculitis should increase suspicion of these pauci-immune primary systemic vasculitides, and an appropriate work-up for systemic involvement should be undertaken. (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">
          "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Predominant deposition of IgM around vessel walls suggests the possibility of vasculitis related to type 2 or type 3 cryoglobulinemia or rheumatoid vasculitis  (
         <a class="graphic graphic_table graphicRef59048" href="/z/d/graphic/59048.html" rel="external">
          table 1
         </a>
         ). Patients with hypocomplementemic urticarial vasculitis may have deposition of IgG, complement, and fibrin on vessel walls, as well as along the dermal-epidermal junction [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">
          "Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">
          "Urticarial vasculitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1117862">
         <span class="h5">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ideally, DIF is performed on a lesion that is
         <strong>
          less than 24 hours old
         </strong>
         . The inflammatory reaction stimulated by the deposition of immunoglobulins in vessel walls quickly results in the destruction of both the vessel wall and the immune complexes, resulting in negative immunofluorescence.
        </p>
        <p>
         In contrast to the biopsies for DIF performed for the evaluation of blistering skin diseases, which are taken from perilesional skin, specimens from vasculitic lesions should be taken from within the lesions. DIF studies cannot be performed on the formalin-fixed tissue obtained for hematoxylin and eosin staining, and a separate tissue specimen should be obtained.
        </p>
        <p>
         Specimens can be placed in Michel's transport medium (a fixative) or normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , or can be flash-frozen with liquid nitrogen. Tissue submitted in saline must be processed within 24 hours. Examination of the specimen by a pathologist experienced in DIF microscopy is preferred.
        </p>
        <p class="headingAnchor" id="H3017402410">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">
          "Society guideline links: Vasculitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H606945">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Cutaneous vasculitis occurs as a result of inflammatory processes that target and damage small or medium-sized blood vessels in the skin  (
         <a class="graphic graphic_table graphicRef59048" href="/z/d/graphic/59048.html" rel="external">
          table 1
         </a>
         ). Cutaneous manifestations of vasculitis may include petechiae, palpable purpura, nodules, ulcers, digital necrosis, livedo reticularis, livedo racemosa, or urticaria. (See
         <a class="local">
          'Types of cutaneous vasculitis'
         </a>
         above and
         <a class="local">
          'When to suspect cutaneous vasculitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – A wide variety of disorders can lead to the development of cutaneous vasculitis. Infections and medications are the most common etiologies of cutaneous small vessel vasculitis. (See
         <a class="local">
          'When to suspect cutaneous vasculitis'
         </a>
         above and
         <a class="local">
          'Evaluation for etiology and extracutaneous involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient assessment
         </strong>
         – The initial evaluation of patients with cutaneous lesions suggestive of vasculitis incorporates confirmation of the presence of vasculitis, assessment for the underlying cause, and the identification of extracutaneous involvement. This includes consideration of a skin biopsy, analysis of the patient history and review of systems, and basic laboratory tests (complete blood count with differential and platelets, comprehensive metabolic panel, and urinalysis with microscopy). A summary of the approach to patients with cutaneous features of small vessel vasculitis is provided in an algorithm  (
         <a class="graphic graphic_algorithm graphicRef138771" href="/z/d/graphic/138771.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Patient assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of skin biopsy
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Biopsy for routine histopathologic examination
         </strong>
         – A skin biopsy is required to confirm a diagnosis of cutaneous vasculitis. Ideally, biopsies for routine histopathologic examination should be taken from a lesion that is 24 to 48 hours old. The best type of biopsy and location for the biopsy depends upon the clinical manifestations. Histopathologic features of vasculitis include fibrinoid necrosis and an inflammatory infiltrate invading or damaging the vessel wall. (See
         <a class="local">
          'Skin biopsy to confirm vasculitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Biopsy for direct immunofluorescence microscopy
         </strong>
         – In patients with cutaneous features of small vessel vasculitis, an additional skin biopsy of lesional skin for direct immunofluorescence (DIF) may be performed at the same time as the biopsy for routine histopathologic examination to assess for IgA vasculitis  (
         <a class="graphic graphic_algorithm graphicRef138771" href="/z/d/graphic/138771.html" rel="external">
          algorithm 1
         </a>
         ). Alternatively, if signs or symptoms of systemic involvement are absent, a biopsy for DIF may be reserved for patients in whom small vessel vasculitis persists for ≥4 weeks. (See
         <a class="local">
          'Direct immunofluorescence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         DIF testing can be a valuable tool for the diagnosis of small vessel vasculitis, as it can help to distinguish immune complex-mediated vasculitides from pauci-immune vasculitis. Ideally, the biopsied lesion should be less than 24 hours old. Biopsy specimens for DIF should
         <strong>
          not
         </strong>
         be placed in formalin. (See
         <a class="local">
          'Biopsy for direct immunofluorescence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with persistent vasculitis or signs of systemic involvement
         </strong>
         – Additional evaluation is indicated for patients with cutaneous vasculitis of uncertain etiology that persists for four or more weeks or who exhibit signs or symptoms suggestive of systemic vasculitis or an associated underlying disease  (
         <a class="graphic graphic_algorithm graphicRef138771" href="/z/d/graphic/138771.html" rel="external">
          algorithm 1
         </a>
         ). For patients with vasculitis of uncertain etiology, this typically includes tests for hepatitis B and C, autoimmune disease, and other disorders associated with vasculitis and a skin biopsy for direct DIF testing (if not already performed). (See
         <a class="local">
          'Additional studies'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology 2010; 56:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol 2005; 17:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennette JC, Falk RJ. The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 2007; 25:S52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu LY, Esparza EM, Anadkat MJ, et al. Cutaneous manifestations of vasculitis. Semin Arthritis Rheum 2009; 38:348.
          </a>
         </li>
         <li class="breakAll">
          Dhadly M, Dean SM, Eberhardt RT. Cutaneous changes in peripheral vascular arterial disease. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI (Eds), McGraw-Hill, 2008. Vol 2, p.1667.
         </li>
         <li class="breakAll">
          Chung L, Kea B, Fiorentino DF. Cutaneous vasculitis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo, JL, Rapini RP, et al. (Eds), Elsevier Limited, 2008. Vol 1, p.347.
         </li>
         <li class="breakAll">
          Piette W. Purpura: Mechanisms and differential diagnosis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier Limited, 2008. Vol 1, p.321.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005; 27:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loricera J, Blanco R, Ortiz-Sanjuán F, et al. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology (Oxford) 2015; 54:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grotz W, Baba HA, Becker JU, Baumgärtel MW. Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge. Dtsch Arztebl Int 2009; 106:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am 2004; 24:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 2008; 35:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachmeyer C, Wetterwald E, Aractingi S. Cutaneous vasculitis in the course of hematologic malignancies. Dermatology 2005; 210:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung SP, Yang YH, Lin YT, et al. Clinical manifestations and outcomes of Henoch-Schönlein purpura: comparison between adults and children. Pediatr Neonatol 2009; 50:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minz RW, Chhabra S, Singh S, et al. Direct immunofluorescence of skin biopsy: perspective of an immunopathologist. Indian J Dermatol Venereol Leprol 2010; 76:150.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13769 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29136340" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20055902" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The histological assessment of cutaneous vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15604905" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical approach to cutaneous vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428368" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The role of pathology in the diagnosis of systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355896" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cutaneous manifestations of vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355896" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cutaneous manifestations of vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355896" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cutaneous manifestations of vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355896" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Cutaneous manifestations of vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314707" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25065012" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20019864" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15120147" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18085729" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18050165" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Vasculitides associated with malignancies: analysis of sixty patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15604537" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cutaneous vasculitis in the course of hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19750891" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical manifestations and outcomes of Henoch-Schönlein purpura: comparison between adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20228544" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Direct immunofluorescence of skin biopsy: perspective of an immunopathologist.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
